On May, 24 Bavarian Nordic A/S (BVNRY) Analysts See $-0.25 EPS

May 16, 2018 - By Richard Doty

Bavarian Nordic A/S (OTCMKTS:BVNRY) Corporate Logo

Earnings report for Bavarian Nordic A/S (OTCMKTS:BVNRY) is awaited on May, 24 before the open., according to Zacks. Analysts predict $-0.25 EPS, which is $0.24 down or 2,400.00 % from 2017’s $-0.01 EPS. -19.35 % EPS growth is what Wall Street’s forecasts after $-0.31 reported EPS previous quarter. Lastly it traded at $9.91.Since May 16, 2017 it’s 0.00% down thus . The stock underperformed the S&P500 by 11.55%.

Bavarian Nordic A/S, a biotechnology company, develops, makes, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer.The firm is worth $960.01 million. The firm markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names.31.66 is the P/E ratio. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: